Ovarian cancer mystery: why do some patients beat platinum therapy?

NCT ID NCT07361471

Recruiting now Knowledge-focused Sponsor: Centre Jean Perrin Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to understand why some ovarian cancer patients respond well to platinum-based chemotherapy for years, while others do not respond at all. Researchers will analyze genetic, clinical, and tissue samples from 55 patients treated at one center. The goal is to find differences that could explain these outcomes, but this is an observational study, not a test of a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help identify why some ovarian cancer patients respond well to platinum chemotherapy while others do not, potentially guiding future treatment choices.
What could go wrong: This is a small, observational study (55 participants) that only looks at past data and tissue samples. It will not directly test a new treatment, so any insights are preliminary and may not change care immediately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Locations

Centre Jean Perrin
RECRUITING

Clermont-Ferrand, PUY DE DOME, 63001, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.